Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions

Dec 10 2013

• By Sue Sutter

Related Content

Canagliflozin Should Have Limitations Based On Renal Function, Panel Says

Jan 11 2013

J&J Gains FDA OK For First-In-Class Type 2 Diabetes Drug Invokana

Mar 29 2013

Dapagliflozin Faces Ominous Prospect Of New Trials

Jan 19 2012

Dapagliflozin’s CV Profile Shines, But FDA Panel Review Falls On Cancer Concerns

Jul 25 2011

Dapagliflozin Cancer Signal Weighs Heavily In FDA Panel's Negative Vote

Jul 19 2011

Related Companies

Bristol Myers Squibb Company

AstraZeneca PLC

Additional Topics

United States Advisory Committees BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window